Tirzepatid caused 20% of the weight loss of obese patients, according to the study

A study by researchers at Yale University in the United States showed that tirzepatid, a pharmaceutical company created by Lilly to control diabetes, can help people who are obese or overweight.

The medication works by mimicking the natural hormones involved in digestion, as patients eat less during the day. Obese people typically manufacture lower levels of these hormones.


Published last Saturday (4/6) in the New England Journal of Medicine, the study included 2,539 participants who were not overweight and obese. The treatment lasted 72 weeks, about a year and a half.

Participants were divided into four groups. Once a week, they received one of three doses of tirzepatid – 5mg, 10mg or 15mg – or a placebo and went on a diet and exercise.

According to scientists, 50% of those given 10 mg doses and 57% of those given 15 mg doses lost 20% or more of their body weight during the study period.

Meanwhile, only 3% of the participants in the placebo group achieved the same feat. People who used tirzepatid also had improvement in all of their predetermined cardiometabolic measures.

“We need to treat obesity as we treat any chronic disease – with effective and safe approaches that drive the mechanisms of the underlying disease – and these results underscore that it is doing so.

Side effects

The most common adverse events in the Tirzepatid study were intestinal symptoms such as vomiting and diarrhea. Most are mild to moderate in severity, especially when the dose is increased.

The drug is not yet for sale in Brazil. Eli Lilly, a pharmacist who only uses the name Lilly here, has not yet been approved to enter the market. In the United States, the pharmaceutical company recently obtained permission to use it to treat diabetes.

Get the news metropolises In your Telegram and stay on top of everything! Access the channel: https://t.me/metropolesurgente.

Leave a Comment